Recurrent chromosomal translocations involving the RARa locus on chromosome 17 are the hallmark of acute promyelocytic leukemia (APL). The RARa gene fuses to variable partners (PML, PLZF, NPM, NuMA and STAT5B: X genes) leading to the expression of APLspecific fusion proteins with identical RARa moieties. To analyse whether the variable X moiety could affect the activity of the fusion protein in vivo, we generated and characterized, on a comparative basis, NPM/RARa transgenic mice (TM) in which the fusion gene is expressed under the control of a human Cathepsin G (hCG) minigene. We compared the features of the leukemia observed in these TM with those in hCG-PML/RARa and hCG-PLZF/RARa TM. In all three transgenic models, leukemia developed after a variably long latency, with variable penetrance. However, the three leukemias displayed distinct cytomorphological features. hCG-NPM/RARa leukemic cells resembled monoblasts. This phenotype contrasts with what was observed in the hCG-PML/RARa TM model in which the leukemic phase was characterized by the proliferation of promyelocytic blasts. Similarly, hCG-PLZF/RARa TM displayed a different phenotype where terminally differentiated myeloid cells predominated. Importantly, the NPM/RARa oncoprotein was found to localize in the nucleolus, unlike PML/RARa and PLZF/RARa, thus possibly interfering with the normal function of NPM. Similarly to what was observed in human APL patients, we found that NPM/ RARa and PML/RARa, but not PLZF/RARa leukemia, was responsive to all-trans retinoic acid (ATRA) or As 2 O 3 treatments. Taken together, our results underscore the critical relevance of the X moiety in dictating the biology of the disease and the activity of the APL fusion oncoprotein.
The chromosomal translocations t(15;17)(q22;q21), t(11;17)(q23;q21) and t(5;17)(q35;q21) are characteristic of acute promyelocytic leukemia (APL) and lead to the fusion of the RARa gene to the PML, PLZF and NPM gene (hereafter referred to as X genes), respectively (Brunning et al., 2001; Sirulnik et al., 2003) . In the fusion proteins encoded by these hybrid genes, identical RARa moieties are fused to structurally unrelated X moieties Sirulnik et al., 2003) . The X/RARa oncoproteins have been proposed to act in a dominantnegative fashion to suppress the physiological function of retinoic acid and X-dependent pathways (Piazza et al., 2001) . Several groups, including our own, have generated PML/RARa and PLZF/RARa transgenic mice (TM) in which the respective fusion genes were placed under the control of human Cathepsin G (hCG) regulatory sequences, thus being expressed in early myeloid progenitors (Grisolano et al., 1997; He et al., 1997 He et al., , 1998 Cheng et al., 1999) . In both TM models, the development of leukemia was observed after a long preleukemic phase, characterized by myeloproliferation, strongly suggesting that additional genetic events are necessary for full-blown leukemogenesis (Grisolano et al., 1997; He et al., 1997 He et al., , 1998 Cheng et al., 1999) . Several studies have emphasized the importance of the deregulation of the X pathways in APL pathogenesis: (i) PML haploinsufficiency in hCG-PML/RARa TM increased the frequency and accelerated the onset of leukemia ; (ii) PLZF inactivation caused a change of the cytomorphological features detected in hCG-PLZF/RARa TM leukemia from mature into immature myeloid cells (i.e. triggered a block of differentiation) ; (iii) the expression of PML/RARa disrupts the localization of wild-type PML, causing it to relocalize from discrete nuclear structures, the PML nuclear bodies, into microspeckled aberrant structures (Dyck et al., 1994; Piazza et al., 2001) . PML/RARa also disrupts the function of cytoplasmic PML, thus impairing TGF-b signaling (Lin et al., 2004) . To determine the functional relevance of the X partners of RARa, we have generated hCG-NPM/RARa TM, and compared the incidence, latency, morphological and immunophenotypic features of leukemia in the three models: hCG-PML/RARa, hCG-PLZF/RARa and hCG-NPM/RARa.
In order to compare the three transgenic models, the same hCG minivector, mouse strain (CBA/BL6), and Transgenic Facility were used. The generation of hCG-PML/RARa and hCG-PLZF/RARa were described elsewhere (He et al., 1997 (He et al., , 1998 . A total of 66 hCG-NPM/RARa, 124 hCG-PML/RARa and 38 hCG-PLZF/RARa TM, as well as non-transgenic littermates (wild-type controls, n ¼ 30) had their automated and differential counts of peripheral blood (PB) monitored monthly. Animals presenting palpable tumors, anemia (Hemoglobinp12 g/dl), thrombocytopenia (Plateletsp500.000/ml) or abnormal cells in PB smears were killed and spleen, liver lymphonode (LN), bone marrow (BM) were collected for analysis. In order to characterize the hematopoiesis in the hCG-NPM/RARa TM, two TM and two littermate controls were killed every 3 months starting from the third month of age, and morphological analysis of PB, BM, spleen, LN and liver was carried out.
Follow-up of hCG-NPM/RARa TM revealed that they developed leukemia with distinct and unexpected features. Table 1 summarizes, in a comparative manner, the main hematological features of leukemia presented by hCG-PML/RARa; hCG-PLZF/RARa and hCG-NPM/RARa TM. In all three models, leukemia was detected after a long latency (in the case of hCG-NPM/ RARa TM was detected only after the first year of life). Leukemia was diagnosed with similar frequency in both hCG-NPM/RARa transgenic lines (five out of 40 (12.5%) and three out of 26 (11.5%) mice from the 7562 and 6305 lines, respectively), as well as in hCG-PML/RARa TM. By contrast, in hCG-PLZF/RARa leukemia was fully penetrant, but occurred again after a long latency. Thus, these fusion proteins are necessary, but not sufficient for leukemogenesis in the mouse. Hepato-and splenomegaly was invariably detected in leukemic TM, regardless of which X/RARa gene is expressed. Leukemia was characterized by anemia, leukocytosis and thrombocytopenia in the three transgenic models (Table 1 ), but leukocyte counts were significantly lower (Po0.05) in NPM/RARa. However, the cytomorphological features of these leukemias were strikingly different in the various models. In hCG-PML/ RARa the leukemic cells resemble promyelocytes in PB and BM, being the closest to human APL, whereas in hCG-PLZF/RARa, no block of myeloid of differentiation was detected with large numbers of mature granulocytes in BM. Although an increase in mature granulocytes was also detected in PB, the difference was not significant (P ¼ 0.16). This leukemia has many of the features of a chronic myelogenous leukemia (CML), albeit being rapidly fatal. hCG-PLZF/RARa TM generated by Cheng et al. (1999) presented the same cytomorphological features described here, nevertheless their model was not fully penetrant and only 5/51 founder mice developed leukemia. In contrast with the APL-like and the CML-like phenotype developed by hCG-PML/RARa and hCG-PLZF/RARa TM, respectively, leukemic hCG-NPM/RARa presented a small The myelomonocytic nature of leukemia was confirmed by immunophenotyping, which demonstrated that the cells were CD117 Figure 1g ). The expression of lysozyme was confirmed by immunohistochemistry as well (Figure 1f inset). Interestingly, Cheng et al. (1999) also generated hCG-NPM/RARa TM, which developed leukemia at a low frequency after a long pre-leukemic phase (>410 days). However, these leukemias were described as ranging from typical APL to CML-like. It must be emphasized, however, that this conclusion was solely based on the analysis of three mice (Cheng et al., 1999) . Furthermore, the differences between our model and those described by Cheng et al. may be owing to the fact that different mouse strains were employed (CBA/BL6 in the present study and C57 by Cheng et al.) .
In hCG-NPM/RARa TM older than 12 months we invariably detected a pre-leukemic phase characterized by: (i) hepato-splenomegaly owing to infiltration by mature granulocytic and monocytoid cells and, (ii) increased myeloid:lymphoid ratio in the BM in the absence of significant changes in the PB. Regarding the existence of a long latency until the development of leukemia, hCG-NPM/RARa TM model was similar to the previously described hCG-PLZF/RARa and hCG-PML/RARa TM models. Therefore, regardless of the fusion gene additional mutagenic events appear to be required for full-blown leukemogenesis.
As PML-RARa and PLZF-RARa accumulate in discrete subnuclear structures in blasts from both human APL patients and TM (He et al., 1997 (He et al., , 1998 Ruthardt et al., 1998; Zhong et al., 2000) , we wanted to determine the subcellular localization of NPM/RARa. We at first stained cells from leukemic TM utilizing an anti-RARa antibody (Ab). The fusion proteins accu- mulated in large nuclear structures, which were reminiscent of nucleoli, the main subcellular structure containing native NPM (Figure 1h) . Indeed, co-staining with anti-nucleolin and anti-RARa Abs demonstrated that NPM-RARa did accumulate in the nucleoli (Figures 1h-j) . This is in agreement with what was reported by Hummel et al. (2002) in COS cells overexpressing different X/RARa fusion proteins: NPM/RARa was found to accumulate predominantly in the nucleolus, whereas PML/RARa and PLZF/ RARa did not (Hummel et al., 2002) . NPM/RARa can heterodimerize with NPM (Redner et al., 2000; Piazza et al., 2001; Sirulnik et al., 2003) . Thus, our results suggest that the fusion protein may deregulate NPM function at the nucleolus through physical interaction. NPM has been recently found mutated in a very high percent of acute myelogenous leukemia (AML), most of which present myelomonocytic (M4) or monocytic (M5) phenotype Falini et al, 2005; Grisendi and Pandolfi, 2005) . As NPM/ RARa is thought to exert a dominant-negative action on NPM, it is conceivable to speculate that the monocytic phenotype detected in hCG-NPM/RARa TM, similar to the one in AML with NPM mutations, could be determined by a loss of NPM function. NPM is implicated in control of ribosome biogenesis, genomic stability and the regulation of ARF nucleolar function, among other things (Okuda, 2002; Kurki et al., 2004; . Therefore, the ability of NPM/ RARa to interfere with NPM may contribute to the leukemic phenotype at multiple levels.
All trans retinoic acid (ATRA) is the mainstay of the treatment of APL (Degos, 2003) . It induces leukemic cell differentiation and disease remission in patients with t(15;17)/PML/RARa or t(5;17)/NPM/RARa. Similarly, As 2 O 3 has been demonstrated to be effective in the treatment of de novo as well as of ATRA-resistant t(15;17)/PML/RARa APL (Degos, 2003) . In contrast, patients with t(11;17)/PLZF/RARa are resistant to ATRA and have a dismaying prognosis. In order to compare the response to ATRA and As 2 O 3 of leukemia in hCG-PLZF/RARa, hCG-PML/RARa and hCG-NPM/RARa TM, we transplanted nude mice (NM) with leukemic cells from the different TM models as previously described and treated the recipients with vehicle (DMSO), ATRA or As 2 O 3 for 21 consecutive days starting on the 25th day post transplant (when invariably leukemic infiltration of PB and BM was detected). Differential counts of PB were performed weekly, whereas BM differential counts were performed in cytospins at the end of treatment (three mice per treatment group of each X/RARa fusion gene) or after death. Treatment with ATRA or As 2 O 3 of NM transplanted with hCG-NPM/RARa or hCG-PML/ RARa leukemic cells resulted in the clearance of leukemic cells and increase of mature granulocytic cells in PB and BM (Table 2) . Interestingly, we did not detect an increase of mature monocytic cells in BM of recipients of hCG-NPM/RARa cells after 21 days of treatment with ATRA, thus suggesting that the differentiation occurred along the granulocytic pathway (Table 2 ). In contrast, no difference was detected in the percentage of blasts and granulocytes between vehicle and ATRA-treatment in NM injected with hCG-PLZF/RARa leukemic cells (Table 2 ). In addition, ATRA significantly prolonged survival of PML/RARa nu mice (NM) were injected i.p. with 5 Â 10 7 leukemic cells. The leukemic cells were obtained from the bone marrow (BM) and spleen of moribund leukemic hCG-PML/RARa, hCG-NPM/ RARa or hCG-PLZF/RARa mice. Those NM that received leukemic cells harboring the same fusion genes (n ¼ 39) were subdivided in three groups according to treatment: vehicle DMSO (n ¼ 13), ATRA 1.5 mg/g of body weight/day (n ¼ 13) or As 2 O 3 5 mg/g/day (n ¼ 13). Drugs were administered through an i.p. daily injection from the 25th day after transplant, and maintained for 21 consecutive days. Three mice per treatment per X/RARa fusion gene group were killed on the 21st day of treatment (46th after transplant) for cytomorphological analysis of PB and BM. The remaining 10 NM were transplanted with hCG-PML/RARa (a), 10 with hCG-NPM/RARa (b) and 10 with hCG-PLZF/RARa (c) leukemic cells and treated with vehicle (red line), ATRA (black line) or As 2 O 3 (blue line) were analysed for cumulative survival. Survival was defined as the time (in days) from transplant until death. All animals relapsed shortly before death and leukemic infiltration was detected in BM and spleen. The survival analysis was based on Kaplan-Mier estimation and groups were compared by the log-rank test using the SPSS 9.0 software (SPSS Inc., Chicago, USA).
NM (median survival time, 95% confidence interval (95%CI) equal to 80 days, 73.8-86.2 days and 59 days, 57.9-60 days in ATRA-treated and controls, respectively, Po0.001) (Figure 2a ) and of NPM/RARa NM (79 days, 95%CI: 74-84 days and 62 days, 95%CI: 58.9-65.1 days in ATRA-treated and controls, respectively, Po0.001) (Figure 2b ). In contrast, PLZF-RARa NM did not respond to ATRA treatment (69 days, 95%CI: 64.8-73.1 days and 63 days, 95%CI: 55.3-70.7 days in ATRA-treated and controls, respectively, P ¼ 0.95) (Figure 2c) . Similar results were observed with As 2 O 3 treatment (Figure 2a-c) , which prolonged median survival of recipients of PML/RARa cells to 71 days, (95%CI: 61.3-80.7 days, P ¼ 0.001) and of NPM/RARa cells to 78 days (95%CI: 74.9-81.1 days, Po0.001), but did not significantly change the survival of NM transplanted with PLZF/RARa cells (67 days, 95%CI: 62.3-71.6 days, P ¼ 0.25). Therefore, our results demonstrate that, similar to what is observed in APL patients, the X moiety of X-RARa fusion proteins determines ATRA and As 2 O 3 sensitivity.
Our comparative analysis of the leukemic phenotypes observed in transgenic models expressing three different APL fusion genes lend further support to the relevance of the X moiety in determining the biology of the disease. It is important to point out that this is the first study comparing leukemogenesis induced by NPM/ RARa, PML/RARa and PLZF/RARa in TM aged out at the same time in the same facility with the same genetic background. In our transgenic models, the expression of the transgene was under the control of hCG promoter, which drives expression in immature myeloid cells with particularly high levels, detected in promyelocytes (Heusel et al., 1993) . Surprisingly, the three models developed leukemia with distinct cytomorphological features. In humans, leukemic cells harboring the t(15;17)/PML/RARa; t(11;17)/PLZF/RARa; t(5;17)/NPM/RARa may vary in morphology, but are undoubtedly classified as APL (Sainty et al., 2000; Brunning et al., 2001) . The expression of the fusion protein in hCG-TM may occur in principle at later stages in hematopoiesis compared to APL patients. Therefore, the resulting phenotype may perhaps be influenced by the stage of differentiation in which the fusion gene is expressed. Nevertheless, in the case of PLZF/RARa we have previously demonstrated that the coexpression of the RARa/PLZF reciprocal product metamorphoses the CML-like phenotype into APL ; it remains to be determined what could be the missing event in the NPM-RARa model.
